BIOLASE Technology, Inc. (NASDAQ: BLTI), the world’s leading dental laser company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) allowing it to market a version of its Waterlase® MD Laser System for use in dermatological applications as well as general and plastic surgery.
Jake St. Philip, Chief Executive Officer, said, “Our singular operational focus today is executing in the dental suite and building on the success of our hard- and soft-tissue dental laser franchise. That said, FDA clearances such as we announced today only serve to build on our proprietary intellectual assets and add value that can be monetized through licensing, partnerships and in some cases future product offerings. We are very pleased with the new indications and applaud the scientific and regulatory teams for this accomplishment.”
Post a Comment